WG
VKTX icon

Winton Group’s Viking Therapeutics VKTX Stock Holding History

Winton Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.53M Buy
+90,546
New +$2.92M 0.11% 216
2026
Q1 		– Sell
-23,762
Closed -$836K – 1386
2025
Q4 		$836K Sell
23,762
-44,938
-65% -$1.59M 0.03% 522
2025
Q3 		$1.81M Buy
+68,700
New +$2.05M 0.07% 283
2021
Q4 		– Sell
-38,927
Closed -$244K – 1415
2021
Q3 		$244K Sell
38,927
-23,911
-38% -$148K 0.01% 1178
2021
Q2 		$376K Sell
62,838
-5,328
-8% -$31.6K 0.02% 1070
2021
Q1 		$431K Sell
68,166
-15,555
-19% -$109K 0.02% 964
2020
Q4 		$471K Sell
83,721
-155,141
-65% -$940K 0.03% 821
2020
Q3 		$1.39M Sell
238,862
-119,239
-33% -$821K 0.05% 677
2020
Q2 		$2.58M Buy
358,101
+90,175
+34% +$599K 0.07% 521
2020
Q1 		$1.25M Sell
267,926
-125,749
-32% -$773K 0.03% 711
2019
Q4 		$3.16M Buy
+393,675
New +$2.87M 0.04% 628
2019
Q2 		– Sell
-21,122
Closed -$210K – 1291
2019
Q1 		$210K Buy
+21,122
New +$177K ﹤0.01% 949

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Winton Group's VKTX Position: Q2 2026 in Review

Winton Group opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 90,546 shares worth $3.53M. The stake represents 0.11% of the portfolio and ranks #216 among its holdings. This is a return to the name: Winton Group previously reported a position in VKTX as recently as Q4 2025.

Winton Group first reported a position in VKTX in Q1 2019 and has held it in 12 quarters since. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Winton Group held 90,546 shares of Viking Therapeutics worth $3.53M as of Q2 2026.
  • Viking Therapeutics was a new Winton Group position in Q2 2026.
  • Viking Therapeutics made up 0.11% of Winton Group's portfolio in Q2 2026, its #216 holding.
  • Winton Group first reported a position in Viking Therapeutics in Q1 2019 and has held it in 12 quarters since.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.